Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial
IJPR-Iranian Journal of Pharmaceutical Research. 2016; 15 (1): 247-252
Dans Anglais
| IMEMR
| ID: emr-177555
ABSTRACT
Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of silymarin among patients on tuberculosis treatment
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Tuberculose pulmonaire
/
Effets secondaires indésirables des médicaments
/
Lésions hépatiques dues aux substances
/
Foie
/
Antituberculeux
Type d'étude:
Essai clinique contrôlé
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Iran. J. Pharm. Res.
Année:
2016
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS